【摘要】 目的:对盐酸莫西沙星与头孢曲松钠联合阿奇霉素治疗中重度老年社区获得性肺炎进行疗效观察及成本-效果评价。方法:选取本院100例中重度老年社区获得性肺炎住院患者,随机分成盐酸莫西沙星组50例和头孢曲松钠联合阿奇霉素组50例,观察两组疗效并进行成本-效果分析。结果:盐酸莫西沙星组和头孢曲松钠联合阿奇霉素组总成本分别为2305.52元和2477.79元;总有效率分别为90.00%和84.00%(P>0.05);成本-效果比分别为25.62和29.50;药物不良反应发生率分别为8.00%和10.00%(P>0.05)。结论:盐酸莫西沙星的治疗方案为中重度老年社区获得性肺炎治疗的较好方案。更多还原

【Abstract】 Objective:To evaluate the clinical consequences and cost-effectiveness of moxifloxacin hydrochloride and combination of ceftriaxone sodium with azithromycin in the treatment of moderate to severe community acquired pneumonia in elderly patients. Methods:A total of 100 elderly patients with moderate to severe community acquired pneumonia in our hospital were randomly divided into moxifloxacin hydrochloride group (n=50) and combination of ceftriaxone sodium with azithromycin group (n=50). The therapeutic effects were monitored and the cost-effectiveness analysis was conducted on the two groups. Results:The total costs of the moxifloxacin group and the combination group were 2 305.52 Yuan and 2 477.79 Yuan; the total effective rates were 90.00% and 84.00%(P>0.05); the cost-effectiveness ratios were 25.62 and 29.50; the incidence of adverse drug reactions were 8.00% and 10.00%(P>0.05),respectively. Conclusion:Moxifloxacin hydrochloride is a better option in the treatment of moderate to severe community acquired pneumonia in elderly patients.更多还原